1. | cyh4426 | |
2. | dmart438201 | |
3. | deoligabri |
1. | cyh4426 | |
2. | dmart438201 | |
3. | deoligabri |
1. | dmart438201 06/07/2018 Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018 |
2. | dmart438201 06/07/2018 Chardan Capital reiterates Buy rating, $40 PT |
3. | cyh4426 04/03/2018 Reports FY EPS loss of $1.63 |